These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30148441)

  • 21. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
    Shafran IH; Alasti F; Smolen JS; Aletaha D
    Ann Rheum Dis; 2020 Jul; 79(7):874-882. PubMed ID: 32371387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
    Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
    Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 30. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.
    Ferraz-Amaro I; Hernández-Hernández MV; Tejera-Segura B; Delgado-Frías E; Macía-Díaz M; Machado JD; Diaz-González F
    Horm Metab Res; 2019 Mar; 51(3):200-209. PubMed ID: 30695794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
    Kawashiri SY; Kawakami A; Yamasaki S; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Ida H; Origuchi T; Ueki Y; Eguchi K
    Rheumatol Int; 2011 Apr; 31(4):451-6. PubMed ID: 20024554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study.
    Toussirot E; Marotte H; Mulleman D; Cormier G; Coury F; Gaudin P; Dernis E; Bonnet C; Damade R; Grauer JL; Abdesselam TA; Guillibert-Karras C; Lioté F; Hilliquin P; Sacchi A; Wendling D; Le Goff B; Puyraveau M; Dumoulin G
    Arthritis Res Ther; 2020 Sep; 22(1):224. PubMed ID: 32993784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.
    Wang J; Devenport J; Low JM; Yu D; Hitraya E
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):882-5. PubMed ID: 26473986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.